Akebia Therapeutics Announces The CMS Has Determined That Vafseo Meets The Criteria For The Transitional Drug Add-On Payment Adjustment In The Anemia Management End-Stage Renal Disease Prospective Payment System Functional Category, Beginning On January 1, 2025.
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics announced that its drug Vafseo has been approved for the Transitional Drug Add-On Payment Adjustment by CMS, starting January 1, 2025. This will provide two years of additional reimbursement for dialysis organizations.
October 10, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics' drug Vafseo has been approved for the TDAPA by CMS, providing two years of additional reimbursement starting January 2025. This approval could enhance the drug's market adoption and financial performance.
The CMS approval for TDAPA means Vafseo will receive additional reimbursement, which is likely to boost its adoption by dialysis organizations. This could lead to increased revenues for Akebia, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100